Altimmune to Participate in the 9th Annual Evercore Healthcare Conference
Globe Newswire•19/11/2026•08:00 ET
0
Key Highlights
- ➤Altimmune management to join Evercore Healthcare Conference fireside chat December 1, 2026
- ➤Pemvidutide remains in late-stage development for metabolic dysfunction-associated steatohepatitis
- ➤Pemvidutide showed robust results in the RECLAIM Phase 2 alcohol use disorder trial
- ➤Pemvidutide is being studied in alcohol-associated liver disease
MORRISTOWN, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 dual receptor agonist, in serious liver diseases, today announced that management will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference on Tuesday, December 1, 2026, at 3:25 p.m. ET.
A webcast of the fireside chat will be available via the Events section of the Altimmune website.
Get started
Create a free account to read the full story.
